文献速递泌尿男性生殖肿瘤

多通路液体活检在前列腺癌耐药机制中的前瞻性评估

Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer.
PubMed 文献 · J Clin Oncol · 2021-07-01

研究利用液体活检从循环肿瘤细胞中检测雄激素受体剪接变异体、AR靶基因和神经内分泌标志物表达,在前瞻性队列(N=99)中发现两个转录聚类,其中C2与更差总生存相关,并在两项多中心II期试验中验证C2独立预后价值。

要点

  • 基于CTC转录本的分层可识别ARSI耐药的不同机制。
  • C2聚类与更差的总生存、PSA-PFS和影像学PFS独立相关。
  • C2预后价值超越AR-V7状态,可用于指导治疗优化。

核心结论

  • 液体活检CTC转录谱可作为转移性前列腺癌独立预后标志物,超越AR-V7,并识别多种ARSI耐药机制。

研究设计与样本

  • 前瞻性队列(N=99)识别基因表达模式,并用两项多中心II期临床试验(恩杂鲁胺N=21,阿比特龙N=27)验证。

主要发现

  • C2在多变量分析中独立于其他临床病理变量。

临床怎么用

  • 可利用CTC转录谱对转移性前列腺癌患者进行风险分层,识别ARSI耐药高危人群。

局限性

  • 研究为前瞻性队列和II期试验验证,需进一步前瞻性试验确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Nearly all men with prostate cancer treated with androgen receptor (AR) signaling inhibitors (ARSIs) develop resistance via diverse mechanisms including constitutive activation of the AR pathway, driven by AR genomic structural alterations, expression of AR splice variants (AR-Vs), or loss of AR dependence and lineage plasticity termed neuroendocrine prostate cancer. Understanding these de novo acquired ARSI resistance mechanisms is critical for optimizing therapy. MATERIALS AND METHODS: A novel liquid biopsy technology was used to collect mRNA from circulating tumor cells (CTCs) to measure expression of AR-Vs, AR targets, and neuroendocrine prostate cancer markers. An institutional review board-approved prospective cohort (N = 99) was used to identify patterns of gene expression. Two prospective multicenter phase II clinical trials of ARSIs for men with castration-resistant prostate cancer (ClinicalTrials.gov: NCT01942837 [enzalutamide, N = 21] and NCT02025010 [abiraterone, N = 27]) were used to further validate these findings. RESULTS: Hierarchical clustering of CTC transcripts identified two distinct clusters. Cluster 2 (C2) exhibited increased expression of AR-regulated genes and was associated with worse overall survival (median 8.6 v 22.4 months; P < .01; hazard ratio [HR] = 3.45 [1.9 to 6.14]). In multivariable analysis, C2 was prognostic independent of other clinicopathologic variables. AR-V status was not significant when accounting for C2. Upon further validation in pooled multicenter phase II trials, C2 was associated with worse overall survival (15.2 months v not reached; P < .01; HR = 8.43 [2.74 to 25.92]), prostate-specific antigen progression-free survival (3.6 v 12 months; P < .01; HR = 4.64 [1.53 to 14.11]), and radiographic progression-free survival (2.7 v 40.6 months; P < .01; HR = 4.64 [1.82 to 17.41]). CONCLUSION: We demonstrate that a transcriptional profile detectable in CTCs obtained from liquid biopsies can serve as an independent prognostic marker beyond AR-V7 in patients with metastatic prostate cancer and can be used to identify the emergence of multiple ARSI resistance mechanisms. This is currently being investigated in additional prospective trials.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Sperger JM, Emamekhoo H, McKay RR, et al. Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. J Clin Oncol. 2021. PMID: 34197212. doi:10.1200/JCO.21.00169

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。